- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07943273
Treatment Outcomes and Molecular Prognostic Factors in TP53 Mutated Myeloid Neoplasms
TP53-mutated myeloid neoplasms encompass biologically heterogeneous disorders with frequent cytogenetic abnormalities and poor outcomes. In myelodysplastic neoplasms, TP53 allelic state contributes to clinical phenotype and prognosis. In acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts, molecular similarities support studying TP53-associated disease across conventional diagnostic boundaries, although pooling lower-risk and advanced diseases can introduce important clinical heterogeneity. Available therapies improve remission in some patients without reliably producing durable disease control. In a pooled analysis of poor-risk cytogenetic AML with TP53 mutations, azacitidine plus venetoclax increased remission compared with azacitidine alone without a corresponding improvement in survival. A recent molecular analysis of the pivotal CPX-351 trial found that benefit was concentrated in AML with myelodysplasia-related mutations rather than TP53-mutated AML. Allogeneic hematopoietic cell transplantation (HCT) can provide prolonged survival in selected patients, but its outcome depends on biological and clinical context. Retrospective transplant data support integrating VAF and cytogenetics, whereas biological-assignment data in MDS suggest that some patients with TP53 mutations benefit from transplantation. the investigators sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure. Our purpose was hypothesis generation rather than causal ranking of regimens or derivation of a validated transplant-selection rule.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Thomas CLUZEAU
- Número de teléfono: +33 0492039025
- Correo electrónico: cluzeau.t@chu-nice.fr
Copia de seguridad de contactos de estudio
- Nombre: Caroline Fileni
- Correo electrónico: fileni.c@chu-nice.fr
Ubicaciones de estudio
-
-
Alpes Maritimes
-
Nice, Alpes Maritimes, Francia, 06000
- CHU de Nice
-
Contacto:
- Thomas CLUZEAU
- Número de teléfono: +33 0492039025
- Correo electrónico: cluzeau.t@chu-nice.fr
-
Contacto:
- Caroline Fileni
- Correo electrónico: fileni.c@chu-nice.fr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
TP53 mutated AML and HR-MDS patients
Descripción
Inclusion Criteria:
- TP53 mutated myeloid AML (> 20% blasts) or HR-SMD
- Age: Age ≥ 18 years
- Allo-HCT was permitted.
- Available NGS analysis at diagnosis
- TP53 VAF > 2%
- Myeloid sarcoma were permitted
- Patients received at least 1 treatment line
Exclusion Criteria:
- TP53 mutations class 1 or 2 or 3 (American College of Medical Genetic and Genomics
- Patients alive at the start of the study who did not receive study information or who objected to the collection of data
- TP53 CCUS or CHIP
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: RETROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
TP53 mutated myeloid neoplasms from Nice University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
|
TP53 mutated myeloid neoplasms from Saint-Louis University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Description of clinical outcomes according to treatment patterns
Periodo de tiempo: Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
We sought to describe treatment patterns in fonction of outcomes in a pooled TP53-associated clinical cohort |
Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
HCT as a time-dependent exposure.
Periodo de tiempo: Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
Description of transplanted patients to assess HCT as a time-dependent exposure. |
Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
|
Pre-HCT TP53 variant allelic frequency (VAF)
Periodo de tiempo: Baseline
|
Variant allelic fraquency of TP53 at diagnosis |
Baseline
|
|
Molecular prognostic
Periodo de tiempo: Baseline
|
To explore survival impact of cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Diagnóstico
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Evaluación de resultados, atención médica
- Evaluación de resultados y procesos, atención médica
- Pronóstico
- Resultado del tratamiento
Otros números de identificación del estudio
- 26Hemato01
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .